Product Images Venlafaxine Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Venlafaxine Hydrochloride NDC 0904-7488 by Major Pharmaceuticals, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
150mg carton label - D962F5AF 7642 4C6E B7BE 3E089FE48873 00
This is a prescription medication for Venlafaxine Hydrochloride Extended-Release Capsules USP, each capsule equivalent to 150 mg of Venlafaxine. The usual dosage and storage instructions are provided, and it is advisable to keep this medication out of the reach of children. The packaging is designed for institutional use only. Manufactured by MAJOR PHARMACEUTICALS, this product is distributed from Indianapolis, USA.*
75mg carton label - D962F5AF 7642 4C6E B7BE 3E089FE48873 01
This text provides information about Venlafaxine Hydrochloride Extended-Release Capsules in a unit dose package. It includes details such as the NDC code, dosage instructions, storage conditions, precautions, and warnings. The capsules contain 75mg of Venlafaxine hydrochloride USP. It also mentions that the package is not child resistant and is intended for institutional use. The product is distributed by Major Pharmaceuticals.*
37.5mg carton label - D962F5AF 7642 4C6E B7BE 3E089FE48873 02
This is a description of Venlafaxine Hydrochloride Extended-Release Capsules USP containing 100 capsules in a unit dose package by Major Pharmaceuticals. Each capsule contains Venlafaxine Hydrochloride equivalent to 375 mg. The usual dosage and storage instructions are provided. The medication guide is included, and caution is advised to keep the drugs out of reach of children. The package is not child-resistant and is for institutional use only. The product is from NDC 5862-527 by Aurbinda Pharma Limited, packaged and distributed by Major Pharmaceuticals in Indianapolis, USA.*
figure - venlafaxine fig1
figure - venlafaxine fig2
This is a list of interacting drugs and their PK fold change with 90% confidence intervals. The mention of medicines like Diazepam, Cimetidine, Ketoconazole, Indinavir, Metoprolol, and Lithium indicates a potential focus on drug interactions and their impact on pharmacokinetics. The text also refers to changes relative to a reference value, suggesting a comparison in drug effectiveness or metabolism.*
figure - venlafaxine fig3
This text seems to be a list of interacting drugs and analytes, along with PK (pharmacokinetic) parameters like Cmax (maximum concentration of a drug) and AU (area under the curve). It also includes information about fold change and 90% CI (confidence interval). The drugs listed include ethanol, aprazolam, indinavir, metoprolol, risperidone, haloperidol, caffeine, tolbutamide, and lithium. Additionally, the analytes mentioned are ethanol, diazepam, desmetyldiazepam, alprazolam, indinavir, metoprolol, imipramine, desipramine, and haloperidol. The information provided in this text can be used to evaluate drug interactions and pharmacokinetics.*
Chemical Structure - venlafaxine str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
